Axsome Therapeutics, Inc. Stock News

Viking Therapeutics is developing innovative medicines in a fast-growing area. Axsome Therapeutics is generating strong sales, and solid regulatory progress could improve things.

MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, and its majority-owned subsidiary, Baergic Bio, Inc. (“Baergic”), today announced that Avenue has entered into an agreement for Baergic to be acquired...

Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator

Axsome Therapeutics remains a 'Sell' due to an undifferentiated CNS pipeline, heavy SG&A, and ongoing net losses despite revenue growth. Auvelity's sales growth appears largely marketing-driven and competes in a crowded, generic-heavy depression market. AXS-05 for Alzheimer's agitation offers some promise as a non-antipsychotic, but real-world adoption and blockbuster potential are limited.

Axsome Therapeutics stock is in a buy zone and is up about 58% this year. The company's biggest revenue generator is a depression treatment.

Axsome Therapeutics, Inc. ( AXSM ) Q3 2025 Earnings Call November 3, 2025 8:00 AM EST Company Participants Darren Opland - Director of Corporate Communications Herriot Tabuteau - Founder, Chairman, CEO & President Nick Pizzie - Chief Financial Officer Ari Maizel - Chief Commercial Officer Mark Jacobson - Chief Operating Officer Conference Call Participants Leonid Timashev - RBC Capital Markets,...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breached their fiduciary duties to shareholders. If you currently own Axsome stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-appr...

Axsome Therapeutics is transitioning into a leading neuroscience company with three marketed drugs and a robust late-stage pipeline. Q2 2025 saw 72% YoY revenue growth, driven by Auvelity and Sunosi, with improving margins and narrowing net losses. AXSM faces risks from competition, regulatory hurdles, and high valuation, but maintains strong cash reserves and disciplined expense control.